DLK Investment Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 13.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,798 shares of the medical instruments supplier's stock after acquiring an additional 2,497 shares during the period. Becton, Dickinson and Company makes up about 2.0% of DLK Investment Management LLC's holdings, making the stock its 23rd largest holding. DLK Investment Management LLC's holdings in Becton, Dickinson and Company were worth $4,764,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company in the first quarter valued at $29,000. REAP Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares in the last quarter. Picton Mahoney Asset Management boosted its holdings in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 54 shares in the last quarter. Nexus Investment Management ULC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth $34,000. Finally, Hopwood Financial Services Inc. purchased a new stake in Becton, Dickinson and Company in the fourth quarter valued at $39,000. 86.97% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on BDX shares. Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. William Blair downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a report on Thursday, May 1st. Finally, Raymond James Financial lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $219.22.
Read Our Latest Stock Report on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In related news, EVP David Shan sold 1,166 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Stock Down 0.3%
BDX stock opened at $171.04 on Thursday. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company's 50-day moving average price is $177.66 and its 200 day moving average price is $210.22. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market cap of $49.02 billion, a P/E ratio of 32.64, a P/E/G ratio of 1.30 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $3.17 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.43%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
